Extended Low-Dose Apixaban After Provoked VTE: Marc Carrier Spotlights Major NEJM Results
Marc Carrier, Professor at Ottawa Hospital Research Institute, has posted on X:
”New in NEJM:
In patients with provoked VTE + enduring risk factors, extended low-dose apixaban (2.5 mg bid ×12 months): reduced recurrent VTE risk by nearly 90% (1.3% vs 10.0%): HR 0.13
Major bleeding was rare (1 pt).”
Find the full study here.
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, and Samuel Z. Goldhaber
Stay updated with Hemostasis Today.
-
Sep 4, 2026, 16:55New Orleans Is Calling ASH26 Is Near
-
Sep 4, 2026, 16:48ESC Congress 2026 – My Top 20 Lipidology Highlights Shaping the Future of Cardiovascular Prevention – Pablo Corral
-
Sep 4, 2026, 16:38Felice Gragnano։ Turning Cardiovascular Risk Into Action
-
Sep 4, 2026, 16:30Lisa Littner: The Hidden Burden of Prior Authorization in Bleeding Disorder Care
-
Sep 4, 2026, 13:54Ahmad G. Alzahrani: A New Classification for Acute Pulmonary Embolism
-
Sep 4, 2026, 12:52James P. Crowley: MDS vs MPN – Understanding the Difference
-
Sep 4, 2026, 12:02Khalid Abdelsamea Mohamedahmed: Routine Blood Parameters in Pediatric Sickle Cell Anemia
-
Sep 4, 2026, 11:37Consuela A. Albright: The Power of Community Advocacy in Sickle Cell Disease
-
Sep 4, 2026, 11:18Aanika Roshni: When Blood, Biology, and Mechanics Intersect